William Blair analyst Brandon Vazquez has maintained their bullish stance on EW stock, giving a Buy rating on August 1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors that suggest Edwards Lifesciences is well-positioned for future growth despite recent regulatory challenges. The FTC’s decision to block the acquisition of JenaValve Technology does not alter the fundamental outlook for the company, as the acquisition was not factored into the current revenue model. This indicates that the company’s growth prospects remain intact without the deal.
Moreover, Edwards Lifesciences has raised its full-year EPS guidance, reflecting stronger-than-expected financial performance. The company is also poised to benefit from ongoing developments in its asymptomatic TAVR and TMTT segments, which are expected to drive revenue growth. These elements combined support the Buy rating, as the company is likely to maintain or accelerate its top-line growth in the coming years.
In another report released on August 1, Piper Sandler also maintained a Buy rating on the stock with a $90.00 price target.